Oppenheimer & Co’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Oppenheimer & Co’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-788	Closed	-$6K	–	1452
2022 Q3	$6K	Hold	788	–	–	﹤0.01%	1357
2022 Q2	$17K	Hold	788	–	–	﹤0.01%	1392
2022 Q1	$30K	Hold	788	–	–	﹤0.01%	1453
2021 Q4	$44K	Buy	788 +270	+52%	+$18.1K	﹤0.01%	1469
2021 Q3	$37K	Sell	518 -120	-19%	-$9.18K	﹤0.01%	1474
2021 Q2	$61K	Buy	638 +100	+19%	+$11K	﹤0.01%	1482
2021 Q1	$79K	Buy	+538	New	+$97.5K	﹤0.01%	1408
2020 Q4	–	Sell	-690	Closed	-$105K	–	1419
2020 Q3	$105K	Buy	+690	New	+$113K	﹤0.01%	1230

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Oppenheimer & Co's NBSE Position: Q4 2022 in Review

Oppenheimer & Co sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2022, closing a stake of 788 shares — an estimated $6K sold.

Oppenheimer & Co first reported a position in NBSE in Q3 2020 and held it in 8 quarters. The position peaked at $105K in Q3 2020. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

Oppenheimer & Co reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Oppenheimer & Co sold 788 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $6K.
Oppenheimer & Co first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2020 and held it in 8 quarters.
Oppenheimer & Co's NeuBase Therapeutics, Inc. Common Stock position peaked at $105K in Q3 2020.
34 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Oppenheimer & Co's 13F filing for Q4 2022, filed 8 Feb 2023.